Eleni Efstathiou, MD, PhD, considers the role of precision medicine in prostate cancer

preview_player
Показать описание
Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, considers the role of precision medicine in prostate cancer and the clinical significance of the PROFOUND trial from the 2021 Genitourinary Cancers Symposium
  1. OBRoncology
Рекомендации по теме
Eleni Efstathiou, MD, 0:02:27

Eleni Efstathiou, MD, PhD, considers the role of precision medicine in prostate cancer

AnCan presentation by 1:28:41

AnCan presentation by Dr. Eleni Efstathiou - 12/19/2022

Eleni Efstathiou, MD, 0:01:00

Eleni Efstathiou, MD, PhD, offers a message for patients on clinical progress in prostate cancer

Eleni Efstathiou, MD, 0:00:57

Eleni Efstathiou, MD, PhD, regarding patients more likely to respond to nivolumab + cabozantinib

Eleni Efstathiou, MD, 0:02:58

Eleni Efstathiou, MD, PhD, offers opinion on the ACIS clinical trial

Eleni Efstathiou, MD, 0:02:03

Eleni Efstathiou, MD, PhD, on whether genetic mutation data impacts the treatment of prostate cancer

Eleni Efstathiou, MD, 0:02:44

Eleni Efstathiou, MD, PhD, regarding the PROSPER clinical trial from ASCO GU 2021

Eleni Efstathiou, MD, 0:01:59

Eleni Efstathiou, MD, PhD, elaborates on the role of chemotherapy in mCRPC

Eleni Efstathiou, MD, 0:02:18

Eleni Efstathiou, MD, PhD, discusses the prostate-specific membrane antigen (PSMA) lutetium

Eleni Efstathiou, MD, 0:01:33

Eleni Efstathiou, MD, PhD, offers opinion on whether CheckMate 9ER is practice-changing

Eleni Efstathiou, MD, 0:02:21

Eleni Efstathiou, MD, PhD, on the practice-changing potential of the PROfound study from ESMO 2020

Eleni Efstathiou, MD, 0:02:02

Eleni Efstathiou, MD, PhD, discusses the CheckMate 9ER clinical trial presented at ESMO 2020

Making advances in 0:01:18

Making advances in prostate cancer

Biomarkers for the 0:01:33

Biomarkers for the management of prostate cancer

Trial of LHRHa, 0:02:45

Trial of LHRHa, abiraterone and enzalutamide: filling an unmet need in prostate cancer therapy

ASCO GU 2022 0:10:25

ASCO GU 2022 - Janssen Highlights Niraparib Combo Data

ASCO 2021: Precision 0:18:13

ASCO 2021: Precision and molecular reporting for prostate cancer

The OncoAlert Tumor 0:53:09

The OncoAlert Tumor Boards Prostate Cancer June 20, 2022

ASCO GU 2019: 0:09:38

ASCO GU 2019: treatment and management of hormone-sensitive metastatic prostate cancer

Neoadjuvant abiraterone acetate 0:05:04

Neoadjuvant abiraterone acetate plus leuprolide acetate for localised high-risk prostate cancer

ASCO GU 2019: 0:18:01

ASCO GU 2019: Updates on non-metastatic castration-resistant prostate cancer (CRPC)

Mary J. Fidler, 0:00:49

Mary J. Fidler, MD, considers whether lurbinectedin may improve outcomes in SCLC

The hype of 0:00:35

The hype of precision medicine

5/15/2023 - Hi-Risk/Recurrent/Advanced 2:30:48

5/15/2023 - Hi-Risk/Recurrent/Advanced PCa Men & Caregiver

visit shbcf.ru